Advertisement

Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography

Published:February 10, 2014DOI:https://doi.org/10.1016/j.clinimag.2014.01.019

      Abstract

      Objective

      The objective was to investigate the prevalence of incidental fluorine-18 fluorodeoxyglucose (FDG) uptake in positron emission tomography/computed tomography.

      Methods

      A total of 11,239 male nonprostate disease patients were included retrospectively.

      Results

      The prevalence of incidental prostate FDG uptake was approximately 1.8%. Among 198 incidental lesions, 100 patients had further examinations; 20 lesions were confirmed to be malignant, while 80 lesions were benign. After logistic regression analysis, age, site, and the maximum standard uptake value were the potent predictors for differentiation of malignant prostate lesions.

      Conclusion

      When focal FDG uptake in the peripheral zone of prostate is detected, especially in elderly men, further clinical evaluation is recommended.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Podoloff DA
        • Ball DW
        • Ben-Josef E
        • Benson AB
        • Cohen SJ
        • Coleman RE
        • Delbeke D
        • Ho M
        • Ilson DH
        • Kalemkerian GP
        • Lee RJ
        • Loeffler JS
        • Macapinlac HA
        • Morgan RJ
        • Siegel BA
        • Singhal S
        • Tyler DS
        • Wong RJ
        NCCN task force: clinical utility of PET in a variety of tumor types.
        J Natl Compr Canc Netw. 2009; 7: S1-S26
        • Wang X
        • Koch S
        Positron emission tomography/computed tomography potential pitfalls and artifacts.
        Curr Probl Diagn Radiol. 2009; 38: 156-169
        • Shie P
        • Cardarelli R
        • Sprawls K
        • Fulda KG
        • Taur A
        Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography.
        Nucl Med Commun. 2009; 30: 742-748
        • Han EJ
        • H O J
        • Choi WH
        • Yoo IR
        • Chung SK
        Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images.
        Br J Radiol. 2010; 83: 915-920
        • Quinn M
        • Babb P
        Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons.
        BJU Int. 2002; 90: 162-173
        • Arcangeli S
        • Pinzi V
        • Arcangeli G
        Epidemiology of prostate cancer and treatment remarks.
        World J Radiol. 2012; 4: 241-246
        • Jadvar H
        • Alavi A
        Role of imaging in prostate cancer.
        PET Clin. 2009; 4: 135-138
        • Engelbrecht MR
        • Barentsz JO
        • Jager GJ
        • van der Graaf M
        • Heerschap A
        • Sedelaar JP
        • Aarnink RG
        • de la Rosette JJ
        Prostate cancer staging using imaging.
        BJU Int. 2000; 86: 123-134
        • Kojima S
        • Zhou B
        • Teramukai S
        • Hara A
        • Kosaka N
        • Matsuo Y
        • Suzuki H
        • Torigoe S
        • Suzuki T
        • Uno K
        • Fukushima M
        Cancer screening of healthy volunteers using whole-body 18 F-FDG-PET scans: the Nishidai clinic study.
        Eur J Cancer. 2007; 43: 1842-1848
        • Shen YY
        • Su CT
        • Chen GJ
        • Chen YK
        • Liao AC
        • Tsai FS
        The value of 18 F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
        Neoplasma. 2003; 50: 217-221
        • Kang KW
        • Kim SK
        • Kang HS
        • Lee ES
        • Sim JS
        • Lee IG
        • Jeong SY
        • Kim SW
        Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18 F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects.
        J Clin Endocrinol Metab. 2003; 88: 4100-4104
        • Takahashi N
        • Inoue T
        • Lee J
        • Yamaguchi T
        • Shizukuishi K
        The roles of PET and PET/CT in the diagnosis and management of prostate cancer.
        Oncology. 2007; 72: 226-233
        • Bouchelouche K
        • Oehr P
        Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review.
        J Urol. 2008; 179: 34-45
        • Powles T
        • Murray I
        • Brock C
        • Oliver T
        • Avril N
        Molecular positron emission tomography and PET/CT imaging in urological malignancies.
        Eur Urol. 2007; 51 ([discussion 1520–1521]): 1511-1520
        • von Mallek D
        • Backhaus B
        • Müller SC
        • Matthies A
        • Palmedo H
        • Jaeger U
        • Biersack HJ
        • Reinhardt M
        Technical limits of PET/CT with 18FDG in prostate cancer.
        Aktuelle Urol. 2006; 37: 218-221
        • Kao PF
        • Chou YH
        • Lai CW
        Diffuse FDG uptake in acute prostatitis.
        Clin Nucl Med. 2008; 33: 308-310
        • Lawrentschuk N
        • Davis ID
        • Bolton DM
        • Scott AM
        Positron emission tomography and molecular imaging of the prostate: an update.
        BJU Int. 2006; 97: 923-931
        • Wilkinson C
        • Chowdhury F
        • Scarsbrook A
        • Smith J
        BCG-induced granulomatous prostatitis—an incidental finding on FDG PET-CT.
        Clin Imaging. 2012; 36: 413-415
        • Lee HY
        • Jeong JY
        • Lee KS
        • Kim HJ
        • Han J
        • Kim BT
        • Kim J
        • Shim YM
        • Kim JH
        • Song I
        Solitary pulmonary nodular lung adenocarcinoma: correlation of histopathologic scoring and patient survival with imaging biomarkers.
        Radiology. 2012; 264: 884-893
        • Stewart GD
        • Gray K
        • Pennington CJ
        • Edwards DR
        • Riddick AC
        • Ross JA
        • Habib FK
        Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score.
        Oncol Rep. 2008; 20: 1561-1567
        • McNeal JE
        The zonal anatomy of the prostate.
        Prostate. 1981; 2: 35-49
        • Muezzinoglu B
        • Gurbuz Y
        Stromal microcalcification in prostate.
        Malays J Pathol. 2001; 23: 31-33
        • Shoskes DA
        • Lee CT
        • Murphy D
        • Kefer J
        • Wood HM
        Incidence and significance of prostatic stones in men with chronic prostatitis/chronic pelvic pain syndrome.
        Urology. 2007; 70: 235-238
        • Roehrborn CG
        • Marks LS
        • Fenter T
        • Freedman S
        • Tuttle J
        • Gittleman M
        • Morrill B
        • Wolford ET
        Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
        Urology. 2004; 63: 709-715
        • Effert PJ
        • Bares R
        • Handt S
        • Wolff JM
        • Büll U
        • Jakse G
        Metabolic imaging of untreated prostate cancer by positron emission tomography with 18 fluorine-labeled deoxyglucose.
        J Urol. 1996; 155: 994-998
        • Hofer C
        • Laubenbacher C
        • Block T
        • Breul J
        • Hartung R
        • Schwaiger M
        Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.
        Eur Urol. 1999; 36: 31-35
        • Ishimori T
        • Patel PV
        • Wahl RL
        Detection of unexpected additional primary malignancies with PET/CT.
        J Nucl Med. 2005; 46: 752-757